<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00628355</url>
  </required_header>
  <id_info>
    <org_study_id>HCRP10272/2007</org_study_id>
    <nct_id>NCT00628355</nct_id>
  </id_info>
  <brief_title>Lidocaine Injection and Ischemic Compression on Chronic Pelvic Pain Treatment</brief_title>
  <official_title>Local Injection of Lidocaine Versus Ischemic Compression in Treatment of Woman With Chronic Pelvic Pain Caused by Abdominal Myofascial Pain Syndrome: Randomized Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is that with comparison of effectiveness of two most common techniques of
      treatment for myofascial pain syndrome (injection of local anesthesia and ischemic
      compression) we could choice the most adequate to treat this disease. This way we could
      decrease the expenses with medicines, examinations, consultations and the time that women
      remains without a diagnosis and treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After evaluation and diagnostic confirmation, the patients will be randomized and submitted
      to the treatment with lidocaine injection or ischemic compression. Each treatment will be
      placed once a week, for four weeks. Women randomized for treatment with Ischemic compression,
      will be first subjected to transcutaneal electrostimulation(TENS), in order to receive
      analgesia on trigger point. The analgesia will be used to inhibit the painful stimulation.
      The device used for this will be the Dualpex 961, with 100 Hertz of frequency and pulse of
      250ms. The intensity will be vary according the painful threshold of each patient. The
      electrostimulation will be made for 30 minutes. The electrodes will be applied around the
      trigger point. After analgesia, the ischemic compression will be applied. This therapy
      consists in a continuous pressure on trigger point. For this we will use one algometer to get
      maximum of homogeneity on therapy. The pressure intensity will be placed by the average
      between the values gotten during three previously measurements of threshold pain in each
      patient. This therapy will be applied three times with duration of 60 seconds each with a 30
      seconds of rest between the applications. Injection of anesthesia: this therapy will be
      applied directly in trigger points with two mL of lidocaine 0.5% with needle of 22 gauges
      directly and perpendicularly in trigger point. The Evaluations for each treatment will be
      carried immediately before the randomization; In one month: immediately after the four weeks
      of treatment; - Three months: three months after the treatment; - Six months: six months
      after the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lidocaine injection group showed significant improvement in pain
  </why_stopped>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of Pain</measure>
    <time_frame>immediately, 1, 3 months after treatment</time_frame>
    <description>The pain will measured by using the visual analogue scale, that is represented by a straight line of 100mm starting at &quot;absence of pain&quot; and ending at point &quot;worst pain experienced or imagined&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Response Rate</measure>
    <time_frame>immediately, 1, 3 months after treatment</time_frame>
    <description>We analyzed the clinical response rate considering significative reduction of 50% of visual analogue scale or significative subjective improvement.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Pelvic Pain</condition>
  <arm_group>
    <arm_group_label>lidocaine injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lidocaine injection. Women randomized for this treatment was submitted to 2 milliliters of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point.
Patients received lidocaine injections once a week for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ischemic compression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation (TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lidocaine</intervention_name>
    <description>Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks</description>
    <arm_group_label>lidocaine injection</arm_group_label>
    <other_name>Lidocaine injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ischemic compression</intervention_name>
    <description>Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.</description>
    <arm_group_label>Ischemic compression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women with chronic diagnosis of pelvic pain;

          2. Women in menacme;

          3. Presence of the diagnostic criteria for abdominal myofascial syndrome;

          4. Agreement with the Term of Free and Clarified Assent.

        Exclusion Criteria:

          1. Endometriosis, interstitial cystitis, syndrome of the irritable intestine or another
             illness that it justifies or it contributes for chronic pelvic pain;

          2. Endometrioma or hernia evidenced to the ultrasound of the abdominal wall.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omero Poli, doctor</last_name>
    <role>Study Director</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center of Chronic Pelvic Pain and Gynecologic Endoscopy of Ribeirao Preto Medical School, University of Sao Paulo</name>
      <address>
        <city>Ribeir√£o Preto</city>
        <state>Sao Paulo</state>
        <zip>14049-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2008</study_first_submitted>
  <study_first_submitted_qc>February 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2008</study_first_posted>
  <results_first_submitted>September 15, 2010</results_first_submitted>
  <results_first_submitted_qc>March 24, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2014</results_first_posted>
  <last_update_submitted>May 23, 2014</last_update_submitted>
  <last_update_submitted_qc>May 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Omero Benedicto Poli Neto</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>lidocaine</keyword>
  <keyword>ischemic compression</keyword>
  <keyword>chronic pelvic pain</keyword>
  <keyword>myofascial pain syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pelvic Pain</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects were recruited at Center of Chronic Pelvic Pain at Hospital das Clinicas of Ribeir√£o Preto Medical School, during 2010. The study was early stopped because the comparator (lidocaine injection) appears significantly more effective.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>TENS Plus Ischemic Compression</title>
          <description>Group received TENS plus ischemic compression</description>
        </group>
        <group group_id="P2">
          <title>Anesthesia Injection</title>
          <description>Group received lidocaine injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ischemic Compression</title>
          <description>Group received TENS plus Ischemic compression</description>
        </group>
        <group group_id="B2">
          <title>Anesthesia Injection</title>
          <description>group received lidocaine injections once a week for 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" spread="3.2"/>
                    <measurement group_id="B2" value="38.5" spread="2.8"/>
                    <measurement group_id="B3" value="37.6" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intensity of Pain</title>
        <description>The pain will measured by using the visual analogue scale, that is represented by a straight line of 100mm starting at &quot;absence of pain&quot; and ending at point &quot;worst pain experienced or imagined&quot;.</description>
        <time_frame>immediately, 1, 3 months after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ischemic Compression</title>
            <description>Group received ischemic compression</description>
          </group>
          <group group_id="O2">
            <title>Anesthesia Injection</title>
            <description>Group received lidocaine injection</description>
          </group>
        </group_list>
        <measure>
          <title>Intensity of Pain</title>
          <description>The pain will measured by using the visual analogue scale, that is represented by a straight line of 100mm starting at &quot;absence of pain&quot; and ending at point &quot;worst pain experienced or imagined&quot;.</description>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>immediately after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.7" spread="22.2"/>
                    <measurement group_id="O2" value="33.7" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0" spread="17.4"/>
                    <measurement group_id="O2" value="27.1" spread="33.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8" spread="24.4"/>
                    <measurement group_id="O2" value="20.8" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response Rate</title>
        <description>We analyzed the clinical response rate considering significative reduction of 50% of visual analogue scale or significative subjective improvement.</description>
        <time_frame>immediately, 1, 3 months after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TENS Plus Ischemic Compression</title>
            <description>Group received TENS plus ischemic compression</description>
          </group>
          <group group_id="O2">
            <title>Anesthesia Injection</title>
            <description>Group received lidocaine injection</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response Rate</title>
          <description>We analyzed the clinical response rate considering significative reduction of 50% of visual analogue scale or significative subjective improvement.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>immediately after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5"/>
                    <measurement group_id="O2" value="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 month after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.8"/>
                    <measurement group_id="O2" value="60.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 months after treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.0"/>
                    <measurement group_id="O2" value="69.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Periodic medical visits and phone calls.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ischemic Compression</title>
          <description>Group received Ischemic compression</description>
        </group>
        <group group_id="E2">
          <title>Anesthesia Injection</title>
          <description>group received lidocaine injections once a week for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <description>3.4 and 5.1 centimeter of extension that resolved spontaneously within 4 and 6 weeks after, respectively</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Omero Benedicto Poli Neto</name_or_title>
      <organization>Ribeirao Preto Medical School - University of Sao Paulo</organization>
      <phone>551636023183</phone>
      <email>polineto@fmrp.usp.br</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

